Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus chemotherapy vs chemotherapy in metastatic triple-negative breast cancer
CTR20212837Phase 3Terminated
- Sponsor
- Suzhou Sundia Biotech Co., Ltd.
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of anlotinib in triple-negative breast cancer (TNBC), sponsored by Suzhou Sundia Biotech Co., Ltd.. Started Nov 2021; status: terminated.
02
Drugs
anlotinib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20212837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212837.